Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of radium-223 (Xofigo) in renal cell carcinoma with bone metastases
2014-003774-16Phase 2Terminated
- Sponsor
- Arctic Therapeutics
- Start
- Jun 2015
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label trial of radium-223 dichloride in renal cell carcinoma (RCC) and bone metastases (2 arms), sponsored by Arctic Therapeutics. Primary endpoints: Maximum tolerated dose (MTD) of Xofigo in Group A (bone metastases only) and Maximum tolerated dose (MTD) of Xofigo in Group B (bone and visceral metastases). Started Jun 2015; status: terminated.
02
Drugs
radium-223 dichloride
03
Conditions
renal cell carcinoma (RCC)bone metastases
Beyond the preview
Go deeper on 2014-003774-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003774-16.